Why did the patent brokers not call back? The single-patent problem and what works instead

A broker's real asset is a network of buyers and a sense of what those buyers want this year. Every package a broker lists costs time to diligence, package, and market, and most of that cost comes back only if the package sells. A single patent in a narrow area, with no evidence that anyone practices it, asks the broker to spend that time on a long shot.

Brokers also screen on the owner. An owner who wants a licensing program rather than a sale, who expects a price the market has not shown, or who cannot supply clean title and prosecution records is harder to serve. None of that is a judgment on the invention.

That matters for the owner who was accepted as much as for the one who was declined. A listing is not a sale. The figures below are dated and describe the brokered market as a whole, not any one broker, and they measure different things, but both point to a minority of listed packages selling, so an owner should plan for a listing to sit.

The same reports describe how the process works when it does work: a broker reaches a large network, and only a small share of the people contacted show any interest. That is a sound method for a package many buyers might want. It is a poor method for a patent that one or two companies need badly.

Families sell better because they give a buyer options: several claim sets, continuations that can still be shaped, and coverage that is harder to avoid. If you hold a single patent with a continuation still possible, that is a question for counsel before you approach anyone, because it can change what you are offering.

The single-patent problem is real, and it is not fatal. It changes the method. Instead of offering the patent to many buyers and waiting for one, you identify the buyer for whom the claims matter most and build the case for that buyer.

Testing the thesis means checking, cheaply and in writing, whether the buyer you have in mind needs the patent, whether they can be reached, and whether a deal would be a license, a sale, or neither. Owners are often right about the buyer and wrong about the deal shape. A buyer who will not buy a patent may license it; a buyer who will not license may want a partnership around a product.

Packaging means a non-confidential summary that explains what the patent covers in the buyer's terms, a map of claims to the buyer's product category, and a data room ready for diligence. Getting into the room means reaching the person who owns the problem, not the general inbox for patent submissions, which in large companies is often designed to say no.

The non-confidential summary is the document that earns the meeting. It names the problem in the buyer's terms, describes the product or capability the claims protect, and explains why the buyer would rather license or buy than build around it. It carries the patent number and nothing that needs an NDA. It does not accuse anyone of anything.

The claims-to-products map is the document the buyer's engineers will read. It shows, at a level counsel is comfortable with, how the claims relate to the buyer's product category. Whether a specific product practices a claim is counsel's question, and the map should be prepared under counsel's direction for that reason.

The data room is the document set the buyer's lawyers will read: the patent and its file history, assignments, maintenance records, any licenses or encumbrances, and the family tree. Gaps in the data room are the most common reason a deal that started well slows down, and they are cheap to find before the first meeting.

Ask the broker or marketplace what their own experience says about time to sale for an asset like yours, and what activity you will see along the way: how many buyers were contacted, how many asked for more, and what they said. If the answers are vague, treat the listing as passive and keep working the direct route in parallel, as long as the listing terms allow it. Check those terms with counsel before you sign them.

Large technology buyers receive far more patent offers than they can review, and they triage hard. The offers that get attention tie the patent to something the buyer is building or selling now, come from someone who understands the buyer's business, and do not read as a threat. An offer that opens with an allegation tends to be routed to litigation counsel, where it stops being a commercial conversation.

Price expectations matter too. Owners who anchor on a figure the market has never shown get a polite decline. Owners who let the buyer's need set the frame, and who can show what it would cost the buyer to go without, get a negotiation.

The mistake is treating a broker's decline as a verdict, or treating a listing as a plan. If a broker takes your package, ask how they will market it, to whom, and for how long, and what happens if it does not sell. If a broker declines, ask why. The reasons are usually specific and useful.

Brokers and Patenture work different problems, so we treat brokers as a referral category in both directions. Patenture takes the owners brokers pass on: single patents, assets below a broker's threshold, and owners who want a licensing program rather than a sale. When a sale mandate needs a broker's buyer network once the package exists, we refer it to a broker. There is no fee share in either direction.

For an owner who already knows the buyer, the work starts with the Mandate Review: about a week, ending in a thesis test, a deal shape, the diligence gaps, and a written yes or no on whether we take the mandate. The Licensing and Sale Mandate follows where the answer is yes, with patent counsel drafting and closing.